The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech’s litifilimab.

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

A U.S. judge ordered federal agencies to restore access to health-related webpages and datasets removed by the Trump ...

Founded in 1978 in Switzerland as one of the first biotech companies, Biogen today (NASDAQ:BIIB) discovers, develops, and ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...